Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Wegener’s Granulomatosis

Staff  |  Issue: August 2007  |  August 1, 2007

Wegener’s granulomatosis (WG) is a rare and complex blood-vessel disease affecting men and women equally. Although the cause of the disease is unknown, it can be treated and managed effectively.

According to the fact sheet by Carol A. Langford, MD, MHS, director of the Center for Vasculitis Care and Research at the Cleveland Clinic, “Most commonly, WG affects the nasal sinuses, lungs, and kidneys, but can also affect the eyes, ears, skin, nerves, joints, and other organs. Because of the variety of potential organ involvement, a wide range of symptoms can develop over days to months. For 90% of people, the first symptoms appear in the respiratory tract (e.g., nose and lungs) and include nasal congestion, frequent nosebleeds, shortness of breath, and cough that may produce bloody phlegm. Other early symptoms can include joint pain, decreased hearing, skin rashes, eye redness and/or vision changes, fatigue, fever, appetite and weight loss, night sweats, and numbness or loss of movement in the fingers, toes, or limbs.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Well-studied therapies have proven effective in treating WG. Although permanent organ damage can still occur, the medications used to treat WG can improve or even resolve organ injury in many instances.

The fact sheet also notes that, “the impact of WG varies greatly between individuals. It’s influenced by the severity of their illness, the organs involved, and any complications related to the disease or its treatment.” People with WG need ongoing checkups that include laboratory studies, imaging tests, and clinic visits with their doctor. Such monitoring is essential to follow the course of WG and to detect or prevent short- or long-term treatment-related complications.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Even with effective treatment, relapses are common. Relapses may resemble or differ from the initial onset, so new symptoms should be reported to the medical practitioner as soon as possible. Regular doctor visits together with laboratory tests and imaging studies can help detect relapses early.

For more details on diagnosing, treating, and living with WG, or to download this and other ACR patient-education fact sheets, visit www.rheumatology.org and follow the links to patient education from the Practice Support menu.

Share: 

Filed under:From the College Tagged with:PatientsWegener's Granulomatosis

Related Articles

    The Granulomatosis of Wegener’s

    May 16, 2011

    Delving deeper into the nonvasculitis aspects of the disease

    Figure 1. A nasal biopsy shows intimal infiltration of the small blood vessels (black arrow).

    Case Illustrates the Difficulty Diagnosing Granulomatosis with Polyangiitis

    June 21, 2018

    Granulomatosis with polyangiitis (GPA) was first described in the British Medical Journal in 1897 by Scottish otolaryngologist Peter McBride.1 GPA is a relatively rare, systemic necrotizing vasculitis that can make diagnosis challenging. The incidence has been estimated anywhere between two and 12 cases per million.2 GPA mainly affects adults between the ages of 45 and…

    Wegener’s Granulomatosis Treatment Today

    October 1, 2008

    WG has an evolving prognosis and treatment course

    Rituximab Maintenance Study: Is Fixed-Schedule or Tailored Dosing Best?

    December 17, 2018

    Rheumatologists prescribe rituximab for induction and maintenance treatment for anti-neutrophil cytoplasm antibody (ANCA) associated vasculitides (AAV). Maintenance treatment typically employs fixed-schedule dosing, but in the recent maintenance of remission using rituximab in systemic ANCA-associated vasculitis II (MAINRITSAN2) trial, researchers from the French Vasculitis Study Group examined whether individually tailored maintenance dosing might work better. “The…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences